Thermo Fisher Scientific Inc.
Thermo Fisher Scientific is a global leader in scientific solutions, playing a critical role in the Oligonucleotide Contract Development and Manufacturing Organization (CDMO) market by providing an extensive array of instruments, reagents, and end-to-end manufacturing services. The company leverages its advanced capabilities for scalable oligonucleotide synthesis, which is essential for producing high-purity therapeutic oligonucleotides such as siRNAs and ASOs. Their integrated approach combines solid-phase synthesis with proprietary purification technologies and automated high-throughput systems, ensuring consistency and quality in large-scale production. Thermo Fisher’s commitment to technological infrastructure is evident in its advanced analytical development, utilizing state-of-the-art technologies like HPLC, LC-MS, and Capillary Electrophoresis (CE) for precise product characterization and stringent quality control at every stage. Furthermore, platforms like the OligoPerfect Primer Designer enable customized oligonucleotide design, accelerating development timelines for a wide range of nucleic acid therapeutics. By providing this robust and comprehensive portfolio, Thermo Fisher Scientific cements its position as a dominant global provider of solutions that drive both fundamental research and the commercialization of oligonucleotide-based drugs.
Latest Market Research Report on Oligonucleotide CDMO Download PDF Brochure Now
Agilent Technologies, Inc.
Agilent Technologies, Inc. is a global leader in analytical and laboratory systems, and a prominent player in the Oligonucleotide CDMO market. The company offers an extensive and comprehensive suite of CDMO services, encompassing custom oligonucleotide synthesis, rigorous process development and optimization, analytical method development, validation, and large-scale GMP (Good Manufacturing Practice) manufacturing for both clinical and commercial applications. Agilent operates multiple state-of-the-art oligonucleotide API (Active Pharmaceutical Ingredient) manufacturing facilities in the United States, which have been regularly and successfully inspected by the U.S. Food & Drug Administration (FDA). These facilities are equipped to produce multi-kilogram lots of oligo APIs, effectively supporting pharmaceutical and biotech customers from grams for toxicology and early-stage clinical trials through to commercial supply. The company’s comprehensive service portfolio, robust quality management system, and deep regulatory compliance expertise, including assistance with international regulatory submissions, make Agilent a highly reliable strategic partner for companies developing and commercializing nucleic acid-based therapeutics.
Bachem
Bachem is a highly specialized, global Contract Development and Manufacturing Organization (CDMO) headquartered in Switzerland, recognized as a key player in the oligonucleotide and peptide markets. The company’s core focus within the oligonucleotide CDMO space is the commercial manufacturing of high-quality oligonucleotide API (Active Pharmaceutical Ingredient). Bachem has built a strong reputation based on its expertise in process optimization, which consistently results in products of exceptional purity, a critical factor for therapeutic applications. As a dedicated, specialized CDMO, Bachem collaborates closely with major pharmaceutical and biotech partners focusing on oligonucleotide and peptide-based therapeutics development. The company’s technologically advanced, GMP-compliant facilities are internationally approved, undergoing regular inspections by prominent regulatory authorities such such as the FDA and Swissmedic. This commitment to stringent quality standards and regulatory compliance, coupled with a focus on specialized molecules, positions Bachem as a trusted and essential partner for expanding global manufacturing capacity and accelerating the production timelines for novel oligonucleotide drugs.
Lonza
Lonza Group AG is a preeminent, diversified global Contract Development and Manufacturing Organization (CDMO), based in Switzerland, known for providing comprehensive, integrated services that span the entire drug development life cycle. Lonza is a foundational player in the broader healthcare industry, and its oligonucleotide CDMO offering strategically leverages its vast experience in biologics and specialized modalities like mRNA and Cell & Gene Therapy (CGT). The company provides end-to-end support for oligonucleotide therapeutics, including process development, scale-up, and cGMP manufacturing across multiple scales. Lonza’s approach aims to streamline the outsourcing process for customers by consolidating multiple services within one expert global organization. By utilizing common equipment platforms, such as the OligoProcess™ unit for larger scale synthesis, Lonza ensures a smooth and efficient transition from early development to Phase II/III clinical supply, with commercial capabilities expanding rapidly. This seamless integration of technology and expertise across the supply chain firmly establishes Lonza as a top-tier CDMO partner for the rapidly growing nucleic acid drug industry.
Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a US-based Contract Development and Manufacturing Organization (CDMO) that provides high-quality, customized services in the oligonucleotide market, leveraging the technological strength of its parent entity, Ajinomoto Co., Inc. The company is engaged in offering custom oligonucleotides, distinguishing itself with its innovative AJIPHASE® synthesis technology. Ajinomoto Bio-Pharma Services supports the full spectrum of development needs, ranging from small-scale synthesis for R&D to large-scale commercial production, catering to preclinical, clinical, and commercial demands. The company has demonstrated a strong commitment to expanding its manufacturing footprint and technological edge, evidenced by a significant investment to expand its oligonucleotide manufacturing capabilities at its U.S. facility. Furthermore, its focus on pioneering technologies, such as the development of a highly functional artificial RNA ligase enzyme, highlights its dedication to advancing the field. Through its integrated services and focus on efficiency and regulatory compliance, Ajinomoto Bio-Pharma Services is a key global player in the Asian and Western oligonucleotide synthesis markets.
Integrated DNA Technologies (IDT)
Integrated DNA Technologies (IDT), a US-based company, is recognized globally for its market leadership in the custom synthesis and distribution of high-quality DNA and RNA oligonucleotides. The company’s core business is centered on providing precision products for genomics applications, with a significant and growing focus on nucleic acid therapeutics and next-generation sequencing (NGS). IDT’s value proposition is built on its commitment to high-quality manufacturing, precision, and rapid turnaround times, positioning it as a preferred partner for specialized oligonucleotide research and development projects. While serving the research community with tailored oligo synthesis services, IDT has also strategically expanded into the CDMO space, opening new therapeutic manufacturing facilities to support the increasing demand for genomic medicines. This expansion allows the company to provide scalable solutions for pharmaceutical developers, ensuring their oligonucleotides meet the stringent quality and regulatory requirements for clinical and commercial use. IDT’s continuous innovation maintains its vital role in the global oligonucleotide supply chain.
Merck KGaA (Life Science)
Merck KGaA, a leading global science and technology company, maintains a significant presence in the oligonucleotide CDMO market, primarily through its Life Science business segment. Operating with a long history and deep scientific expertise, Merck provides a wide array of products essential for oligonucleotide synthesis and analysis, including DNA oligos, RNA oligos, predesigned primers, and qPCR probes for diverse applications in research and diagnostics. The company’s strategic vision involves supporting the entire value chain of oligonucleotide-based therapeutics. This commitment was recently strengthened through the acquisition of key manufacturing capabilities, such as Exelead, which significantly expanded its capacity for lipid nanoparticle, liposome, and oligonucleotide manufacturing. By integrating these capabilities, Merck can offer end-to-end solutions that support drug developers from fundamental research to large-scale clinical and commercial production. Merck’s dedication to quality, its robust supply chain, and its focus on tackling complex diseases solidify its position as a major and influential player in the global oligonucleotide CDMO landscape.
Danaher Corporation
Danaher Corporation is a diversified global science and technology conglomerate that is a major player in the oligonucleotide synthesis and CDMO market through its strategic life sciences and diagnostics operating companies. These subsidiary brands, such as Beckman Coulter and Cytiva (formerly GE Healthcare Life Sciences), leverage Danaher’s continuous improvement business system to establish a strong foothold in the market. Danaher’s portfolio includes technology solutions and robust systems that facilitate the high-throughput oligonucleotide synthesis, process optimization, and complex molecular analysis required for modern drug development. Cytiva, for instance, provides the necessary tools and systems—including the OligoSynt and OligoProcess platforms—that empower manufacturers with the technology for large-scale, cost-efficient oligonucleotide production, supporting all stages from discovery to commercial manufacturing. By focusing on strategic acquisitions and providing essential technological infrastructure, Danaher ensures its subsidiaries remain at the forefront of providing reliable, scalable, and high-quality solutions for the nucleic acid medicine industry globally.
Kaneka Eurogentec S.A.
Kaneka Eurogentec S.A., a subsidiary of the Japanese multinational Kaneka Corporation, is an important European Contract Development and Manufacturing Organization (CDMO) in the oligonucleotide market. Based in Belgium, the company specializes in providing high-quality, custom-made nucleic acid services and products, including oligonucleotide synthesis for research, diagnostics, and therapeutics. Kaneka Eurogentec leverages its extensive experience and the resources of its parent company to offer services that meet the stringent regulatory requirements of the pharmaceutical industry. The company is dedicated to providing efficient solutions for its partners, supporting the development of next-generation oligonucleotide-based drugs. Its focus on specialized manufacturing and quality assurance ensures the supply of reliable raw materials and APIs. Through its significant presence and contribution, Kaneka Eurogentec helps drive the growth of the European oligonucleotide market by offering comprehensive and high-quality CDMO support.
WuXi TIDES (WuXi AppTec)
WuXi TIDES is a specialized Contract Research, Development and Manufacturing (CRDMO) platform that is a key business unit of the global R&D and manufacturing powerhouse, WuXi AppTec. The platform is dedicated to ‘TIDES’ drugs, which include therapeutic peptides, oligonucleotides, and related synthetic conjugates. WuXi TIDES offers a fully integrated, efficient, flexible, and high-quality solution that spans the entire drug development and manufacturing lifecycle, from early discovery and research through to preclinical, clinical, and commercial supply. Its oligonucleotide CDMO services are designed to manage the complexities of modern nucleic acid-based drugs, providing partners with robust process development, high-purity synthesis, and seamless scale-up. By leveraging WuXi AppTec’s comprehensive global network and quality standards, WuXi TIDES is positioned as a trusted partner that helps pharmaceutical and biotech companies accelerate their pipelines and bring innovative oligonucleotide therapies to market globally.
Nitto Avecia
Nitto Avecia is a US-based contract manufacturer that is a leading force in the oligonucleotide CDMO market, with a reputation for having one of the largest manufacturing footprints globally. Acquired by the Japanese firm Nitto Denko, the company specializes in the development, manufacturing, and modification of a broad range of oligonucleotides, including Antisense Oligonucleotides (ASOs) and small interfering RNAs (siRNAs). Nitto Avecia’s primary strength is its significant production capacity, which is specifically designed to meet the high-volume demands of preclinical, clinical, and commercial oligonucleotide programs. The company’s expertise is crucial for nucleic acid drug development, as it ensures a reliable and scalable supply of high-quality drug substance. By focusing exclusively on contract manufacturing for nucleic acid drugs and continuously expanding its capabilities, Nitto Avecia plays a vital role in supporting the pharmaceutical industry’s need for large-scale, high-quality oligonucleotide APIs.
GenScript
GenScript Biotech is a global contract research organization (CRO) that has significantly expanded its service offering to include comprehensive CDMO capabilities in the oligonucleotide market. The company provides custom solutions that cater to a wide range of needs, from small-scale research-grade synthesis to large-scale, high-quality manufacturing for therapeutic applications. GenScript’s oligonucleotide services are a critical component for biotech and pharmaceutical companies, supporting the development of antisense oligonucleotides (ASOs), siRNAs, and other nucleic acid-based medicines. Their commitment to offering cost-effective and flexible manufacturing options, coupled with strong technical expertise, has allowed GenScript to establish an emerging yet powerful presence in the global CDMO landscape. By delivering scalable solutions and custom support, GenScript helps its partners accelerate the transition of novel nucleic acid therapies from the discovery phase into clinical and commercial development, thereby contributing significantly to the broader genomic medicine sector.
Latest Market Research Report on Oligonucleotide CDMO Download PDF Brochure Now